About Cell IDx
Cell IDx is a company based in San Diego (United States) founded in 2012 was acquired by Leica Biosystems in November 2022. Cell IDx has raised $1.34 million across 2 funding rounds from investors including Leica Biosystems. Cell IDx offers products and services including Tissue Processors, Digital Pathology Scanners, and IHC Primary Antibodies. Cell IDx operates in a competitive market with competitors including HYCOR BioMedical, Exagen, Kypha, Lophius Biosciences and SmartHealth, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cell Idx, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.34 M (USD)
in 2 rounds
-
Latest Funding Round
$1.34 M (USD), Seed
Dec 21, 2021
- Investors
-
Employee Count
Not available
-
Acquired by
Leica Biosystems
(Nov 08, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cell IDx
Cell IDx offers a comprehensive portfolio of products and services, including Tissue Processors, Digital Pathology Scanners, and IHC Primary Antibodies.
Devices for preparing tissue samples in diagnostics
Scanners for high-quality slide imaging in research
Antibodies for immunohistochemistry applications
People of Cell IDx
Unlock access to complete
Unlock access to complete
Funding Insights of Cell IDx
Cell IDx has successfully raised a total of $1.34M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.34 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cell IDx
Cell IDx has secured backing from 1 investor. Prominent investors backing the company include Leica Biosystems.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides tools for anatomic pathology, histology, and digital cancer diagnostics worldwide.
|
Locked | Locked | Locked |
Investor details for Cell IDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cell IDx
Investment portfolio details for Cell IDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cell IDx
Detailed financials for Cell IDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cell Idx Comparisons
Peer comparison for Cell IDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cell IDx
Cell IDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HYCOR BioMedical, Exagen, Kypha, Lophius Biosciences and SmartHealth, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of diagnostic instruments and reagents for autoimmune diseases and allergies
|
|
| Locked | Locked | Locked |
Diagnostic and monitoring solutions for autoimmune connective diseases are developed.
|
|
| Locked | Locked | Locked |
Diagnostic biomarker tests for inflammation and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
T-cell-based diagnostics for infectious and immune diseases are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostics for vascular, metabolic, and oncological diseases are developed.
|
|
| Locked | Locked | Locked |
Molecular diagnostics kits, instruments, and software are developed and manufactured.
|
Detailed competitors of Cell IDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cell Idx
Complete news archive for Cell IDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cell IDx
Cell IDx was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Cell IDx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Cell IDx is a funded company, having raised a total of $1.34M across 2 funding rounds to date.
Cell IDx was founded in 2012 and is based in San Diego, United States. Operations focus on the biotechnology sector, where highly sensitive reagents for research and clinical immunohistochemistry, as well as other immunoassays, are developed. Products such as ultrapolymer enzyme conjugates, ultraplex immunohistochemistry kits, and ancillary reagents are offered. Biomolecules are also conjugated and immobilized with emphasis on high yields and activity retention.
Cell IDx's top competitors include Exagen, SmartHealth and HYCOR BioMedical.
Cell IDx offers Tissue Processors, Digital Pathology Scanners, and IHC Primary Antibodies.
Cell IDx has 1 investor. Key investors include Leica Biosystems.